Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Deciphera’s Rare Tumor Drug Grabs US Approval
Deciphera Pharmaceuticals, now a wholly owned subsidiary of Ono Pharmaceutical, has received regulatory approval in the US for its kinase inhibitor Romvimza (vimseltinib) for the treatment of symptomatic tenosynovial giant cell tumors (TGCTs). The FDA approved the drug on February…
To read the full story
Related Article
- Deciphera’s Romvimza Scores EU Nod as First TGCT Therapy
September 19, 2025
- Deciphera’s TGCT Drug Gets Key EMA Backing: Ono
July 29, 2025
- Deciphera’s TGCT Drug Accepted for Review in Europe: Ono
July 22, 2024
- Ono Completes Acquisition of Deciphera
June 13, 2024
- Ono Picks Up Deciphera in US$2.4 Billion Deal to Extend Pipeline, Market Channels
May 1, 2024
BUSINESS
- Positive Price Revisions Seen at Several Firms in FY2026 Reform: Poll
March 6, 2026
- Japan Grants First-Ever Approval to iPSC-Based Therapies
March 6, 2026
- Meiji Starts Japan PIII Trial of Rezurock for CLAD
March 6, 2026
- Meiji Rolls Out Rezurock in Taiwan
March 6, 2026
- Toray Out-Licenses Parkinson’s Drug to Immunis
March 6, 2026
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…